Latest Remuneration News

DMC Mining Limited reported a $206,000 net cash outflow for Q4 2024, with a cash balance dwindling to $33,000. The company has secured a $525,000 loan and is actively pursuing additional funding to support its upcoming public offer and operational needs.

European Metals Holdings has made significant strides in developing its Cinovec Lithium Project, announcing a strategic relocation of its processing plant and ongoing enhancements to production capacity and cost efficiency. The Definitive Feasibility Study is on track for mid-2025 completion, promising a clearer outlook on the project's economic potential.

Toro Energy reports steady progress in its Wiluna Uranium Project with updated resource estimates and ongoing native title consultations, positioning itself to capitalize on improving uranium market conditions.

Somerset Minerals Ltd has taken a significant step forward by entering a conditional agreement to acquire the high-grade Coppermine Project in Nunavut, Canada, while completing the sale of its Valle del Tigre II mineral concession in Ecuador. Preparations are underway for a maiden exploration campaign at Coppermine, targeting substantial copper-silver mineralisation.

Bounty Oil and Gas NL reports steady cash reserves and rising oil production in Queensland, while facing regulatory setbacks offshore. The company’s strategic developments and entitlement offer position it for growth in 2025.

Mustera Property Group progresses design and marketing for its McCabe Street development while maintaining sales momentum at Forbes Residences, alongside a notable executive remuneration update.

Hexima Limited has called off its planned acquisition of AI developer Real Thing Entertainment, ending the quarter with $1.64 million in cash and a cautious outlook on future strategic moves.

Health and Plant Protein Group Limited reported a decline in cash reserves to $0.90 million for Q2 FY25, continuing its efforts to resolve a US tax withholding issue tied to a previous asset sale.

Kalium Lakes Limited reports progress on its recapitalisation plan following operational setbacks and administration, while shares remain suspended on the ASX.

Prescient Therapeutics has secured FDA clearance for its PTX-100 Phase 2 trial targeting relapsed/refractory cutaneous T-cell lymphoma, while also appointing James McDonnell as its new CEO. The company reports steady progress in its cell therapy platforms and maintains a solid cash position bolstered by a recent R&D tax rebate.

Range International Limited has appointed Russell Kennett as its new CEO, marking a pivotal step in the company’s growth strategy. The move comes alongside an update to Executive Chairman Richard Jenkins’ remuneration, underscoring leadership continuity.

Mindax Limited progresses its Mid-West Shared Infrastructure Project and seeks development partners for the Mt Forrest Iron Project, while securing a significant R&D tax incentive refund.